GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Abeona Therapeutics Inc (NAS:ABEO) » Definitions » Cyclically Adjusted PB Ratio

Abeona Therapeutics (Abeona Therapeutics) Cyclically Adjusted PB Ratio : (As of May. 24, 2024)


View and export this data going back to 1980. Start your Free Trial

What is Abeona Therapeutics Cyclically Adjusted PB Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


Abeona Therapeutics Cyclically Adjusted PB Ratio Historical Data

The historical data trend for Abeona Therapeutics's Cyclically Adjusted PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Abeona Therapeutics Cyclically Adjusted PB Ratio Chart

Abeona Therapeutics Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Abeona Therapeutics Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cyclically Adjusted PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Abeona Therapeutics's Cyclically Adjusted PB Ratio

For the Biotechnology subindustry, Abeona Therapeutics's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Abeona Therapeutics's Cyclically Adjusted PB Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Abeona Therapeutics's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Abeona Therapeutics's Cyclically Adjusted PB Ratio falls into.



Abeona Therapeutics Cyclically Adjusted PB Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PB Ratio takes the Book Value per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/B calculation. Because it considers this 10-year average, it's often referred to as the CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio.

Abeona Therapeutics's Cyclically Adjusted Book per Share for the quarter that ended in Mar. 2024 is calculated as:

For example, Abeona Therapeutics's adjusted Book Value per Share data for the three months ended in Mar. 2024 was:

Adj_Book=Book Value per Share/CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=-0.322/131.7762*131.7762
=-0.322

Current CPI (Mar. 2024) = 131.7762.

Abeona Therapeutics Quarterly Data

Book Value per Share CPI Adj_Book
201406 -1,342.250 100.560 -1,758.925
201409 -1,419.785 100.428 -1,862.969
201412 6.032 99.070 8.023
201503 3.949 99.621 5.224
201506 50.189 100.684 65.688
201509 55.818 100.392 73.268
201512 51.706 99.792 68.278
201603 50.134 100.470 65.755
201606 46.866 101.688 60.733
201609 47.090 101.861 60.920
201612 61.545 101.863 79.619
201703 59.437 102.862 76.144
201706 55.278 103.349 70.483
201709 54.906 104.136 69.480
201712 90.694 104.011 114.904
201803 89.556 105.290 112.085
201806 85.000 106.317 105.355
201809 78.343 106.507 96.930
201812 69.896 105.998 86.894
201903 61.415 107.251 75.459
201906 54.396 108.070 66.329
201909 47.034 108.329 57.214
201912 53.344 108.420 64.835
202003 39.576 108.902 47.889
202006 35.696 108.767 43.247
202009 34.050 109.815 40.859
202012 26.669 109.897 31.979
202103 23.826 111.754 28.095
202106 20.762 114.631 23.867
202109 19.571 115.734 22.284
202112 7.195 117.630 8.060
202203 5.345 121.301 5.807
202206 3.422 125.017 3.607
202209 2.009 125.227 2.114
202212 1.510 125.222 1.589
202303 1.045 127.348 1.081
202306 0.435 128.729 0.445
202309 0.892 129.860 0.905
202312 0.559 129.419 0.569
202403 -0.322 131.776 -0.322

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Abeona Therapeutics  (NAS:ABEO) Cyclically Adjusted PB Ratio Explanation

Compared with the regular PB Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PB Ratio smoothed out the fluctuations of book value during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PB Ratio should give similar results to regular PB Ratio.


Abeona Therapeutics Cyclically Adjusted PB Ratio Related Terms

Thank you for viewing the detailed overview of Abeona Therapeutics's Cyclically Adjusted PB Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Abeona Therapeutics (Abeona Therapeutics) Business Description

Traded in Other Exchanges
Address
1330 Avenue of the Americas, 33rd Floor, New York, NY, USA, 10019
Abeona Therapeutics Inc is a clinical-stage biopharmaceutical company. The firm is focused on developing gene therapies and plasma-based products for life-threatening rare genetic diseases. Its lead clinical programs consist of EB-101, autologous, gene-corrected cell therapy for recessive dystrophic epidermolysis bullosa; ABO-102, adeno-associated virus-based gene therapy for Sanfilippo syndrome type A, and ABO-101, an AAV-based gene therapy for Sanfilippo syndrome type B.
Executives
Mark Alvino director C/O SCO SECURITIES LLC, 1285 AVENUE OF THE AMERICAS 35TH FLOOR, NEW YORK NY 10019
Michael Amoroso officer: Chief Operating Officer 1330 AVENUE OF THE AMERICAS, 33RD FLOOR, NEW YORK NY 10019
Faith L. Charles director ABEONA THERAPEUTICS INC., 1330 AVENUE OF THE AMERICAS - FLOOR 33, NEW YORK NY 10019
Vishwas Seshadri director, officer: Chief Executive Officer 64 STRYKER COURT, BRIDGEWATER NJ 08807
Leila Alland director C/O PMV PHARMACEUTICALS, INC., 8 CLARKE DRIVE, SUITE 3, CRANBURY NJ 08512
Christine Berni Silverstein officer: Chief Financial Officer C/O ABEONA THERAPEUTICS INC., 1330 AVENUE OF THE AMERICAS, 33RD FLOOR, NEW YORK NY 10019
Joseph Walter Vazzano officer: Chief Financial Officer 1330 AVENUE OF THE AMERICAS, 33RD FLOOR, NEW YORK NY 10019
Brendan M. O'malley officer: SVP, General Counsel 1330 AVENUE OF THE AMERICAS, 33RD FLOOR, NEW YORK NY 10019
Adage Capital Partners, L.p. 10 percent owner 200 CLARENDON STREET, 52ND FLOOR, BOSTON MA 02116
Adage Capital Management, L.p. 10 percent owner 200 CLARENDON STREET, 52ND FLOOR, BOSTON MA 02116
Adage Capital Partners Gp, L.l.c. 10 percent owner 200 CLARENDON STREET, 52ND FLOOR, BOSTON MA 02116
Robert Atchinson 10 percent owner 200 CLARENDON STREET, 52ND FLOOR, BOSTON MA 02116
Phillip Gross 10 percent owner 200 CLARENDON STREET, 52ND FLOOR, BOSTON MA 02116
Edward Carr officer: Vice President, Controller 1330 AVENUE OF THE AMERICAS, 33RD FLOOR, NEW YORK NY 10019
Todd Wider director 4848 LEMMON AVENUE, SUITE 517, DALLAS TX 75219